


IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: IMGN

Last Trade:	6.01
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.06  (-0.988%)
Day Range	5.90 - 6.14
52-Week Range	1.51 - 8.04
Volume	1,399,893

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology.

ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FR α -positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla[®], in other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, B... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 1, 2017*
[ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference](#)
- Jul 28, 2017*
[ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results](#)
- Jul 14, 2017*
[ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results](#)
- Jun 26, 2017*
[ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia](#)
- May 30, 2017*
[ImmunoGen and Sanofi Amend License Agreements](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Aug 25, 2016*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)